Aptose Biosciences Inc. (NASDAQ:APTO) Short Interest Update

Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) was the target of a significant growth in short interest during the month of December. As of December 15th, there was short interest totalling 187,800 shares, a growth of 84.5% from the November 30th total of 101,800 shares. Based on an average daily volume of 6,130,000 shares, the days-to-cover ratio is currently 0.0 days. Approximately 0.3% of the company’s stock are short sold.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on APTO shares. HC Wainwright reiterated a “buy” rating and set a $2.00 price objective on shares of Aptose Biosciences in a research note on Tuesday, December 10th. StockNews.com initiated coverage on Aptose Biosciences in a research report on Monday, December 23rd. They issued a “hold” rating on the stock.

Hedge Funds Weigh In On Aptose Biosciences

An institutional investor recently raised its position in Aptose Biosciences stock. Sigma Planning Corp raised its stake in Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) by 71.3% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 401,750 shares of the biotechnology company’s stock after acquiring an additional 167,282 shares during the quarter. Sigma Planning Corp owned approximately 2.22% of Aptose Biosciences worth $165,000 as of its most recent filing with the Securities & Exchange Commission. 26.62% of the stock is currently owned by institutional investors.

Aptose Biosciences Trading Down 3.9 %

NASDAQ APTO traded down $0.01 on Friday, hitting $0.24. 2,424,998 shares of the company were exchanged, compared to its average volume of 1,790,199. The stock has a fifty day moving average of $0.28 and a 200-day moving average of $0.45. Aptose Biosciences has a 12 month low of $0.13 and a 12 month high of $2.68. The company has a market cap of $14.50 million, a PE ratio of -0.08 and a beta of 1.06.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.